Focused on solving unmet needs in ophthalmology

Our pipeline of topical drug candidates promises improvement in drug delivery for the back- and front-of-the-eye

Changing the paradigm in DME

Developing non-invasive therapy for DME, a leading cause of blindness

Taking a new approach in managing dry eye disease

The potential to be the first topical biologic for ophthalmic use

Simplifying treatment for post-cataract surgery inflammation

The potential for fewer daily drops and improved compliance

Disruptive new technologies for ophthalmic topical treatment

Enabling new topical options for patients with eye diseases